1 |
Carrasco-Ceballos JM, Barrera-Hernández D, Locia-Espinosa J, Sampieri CL, Lara-Reyes JA, Hernández-Aguilar ME, Aranda-Abreu GE, Toledo-Cárdenas MR, Chi-Castañeda LD, Pérez-Estudillo CA, Rojas-Durán F. Involvement of the PRL-PAK1 Pathway in Cancer Cell Migration. Cancer Diagn Progn 2023;3:17-25. [PMID: 36632591 DOI: 10.21873/cdp.10174] [Reference Citation Analysis]
|
2 |
Liang J, Deng Y, Zhang Y, Wu B, Zhou J. PRLR and CACNA2D1 Impact the Prognosis of Breast Cancer by Regulating Tumor Immunity. J Pers Med 2022;12. [PMID: 36556307 DOI: 10.3390/jpm12122086] [Reference Citation Analysis]
|
3 |
Lee H, Lee I, Kang K, Park S, Jung M, Yang SG, Kwon T, Lee D. A Network Pharmacology Study to Uncover the Mechanism of FDY003 for Ovarian Cancer Treatment. Natural Product Communications 2022;17:1934578X2210754. [DOI: 10.1177/1934578x221075432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Huang L, Dai G. Long non-coding RNA DCST1-AS1/hsa-miR-582-5p/HMGB1 axis regulates colorectal cancer progression. Bioengineered 2022;13:12-26. [PMID: 34967274 DOI: 10.1080/21655979.2021.1976894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|